[Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck]

Laryngorhinootologie. 2022 Sep;101(9):736-740. doi: 10.1055/a-1830-8298. Epub 2022 May 16.
[Article in German]
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cetuximab / therapeutic use
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Squamous Cell Carcinoma of Head and Neck

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab
  • Cetuximab